adverse events temporally associated with infusion

In biological field, it is pretty common to collect and analyze the adverse events that are temporally associated with an infusion. For example, this is required in a recent FDA guidance about IGIV (http://www.fda.gov/cber/gdlns/igivimmuno.pdf). The guidance stated “Your protocol should define criteria for establishing an AE as an infusional AE (i.e., an AE temporally associated with an infusion). We recommend you list AEs individually by body system with subject identification numbers and report the overall incidences of all AEs that occur during or within: (a) 1 hour, (b) 24 hours, and (c) 72 hours following an infusion of test product, regardless of other factors that may impact a possible causal association with product administration.”

While this is understandable, we need to be clear about the exact time frame for collecting these AEs when coming to the programming. I had a couple of studies where the definition (therefore the calculation) of the infusion related adverse events are defined differently “Infusion related adverse events are defined as any event that occurs within 1 hour, 24 hours, or 72 hours of initiation of the study drug infusion.” While this is not wrong, the time frame is shorter for counting the infusion related adverse events.

To be crystal clear about the time period where the infusion related AEs are collected, the following sentence seems to be better.

“The incidence of adverse events considered potentially related to Flebogamma 5% DIF during or within 72 hour after completing an infusion…” (refer to http://www.ncbi.nlm.nih.gov/pubmed/17909953?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum”